A Confirmation Study of Eribulin in Combination With Capecitabine
Status:
Completed
Trial end date:
2015-10-13
Target enrollment:
Participant gender:
Summary
This is a Phase 1b/2, multi-center, open-label, dose escalation (in 2 different dosing
schedules [1 and 2]) and dose-confirmation study of eribulin administered in combination with
capecitabine.